Fangyu Peng1, Galina Rabkin, Otto Muzik. 1. The Carman & Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, USA. fpeng@pet.wayne.edu
Abstract
PURPOSE: The purpose of this study was to study the use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography (F-18 FDG PET) for monitoring therapeutic response by rhabdomyosarcoma (RMSA) in children. PATIENTS AND METHODS: A retrospective case study was performed by searching a computer database for the patients with RMSA in whom F-18 FDG PET studies were performed pre- and posttreatment. The data of the PET studies from these patients were analyzed in conjunction with clinical treatment and other imaging studies to determine whether interval changes of F-18 FDG uptake by the RMSA reflect response of RMSA to treatment. RESULTS: Four patients with RMSA who received both pretreatment and posttreatment F-18 FDG PET studies were identified from the database and included in this study. A dramatic decrease of F-18 FDG uptake by the tumor was evident in the patients who had a favorable response to the therapy and prolonged remission of the disease. In contrast, persistent abnormal FDG uptake in one patient was associated with early relapse of the RMSA. CONCLUSIONS: F-18 FDG PET may be useful for monitoring therapeutic response by RMSA in children, which needs to be verified with a prospective study in a larger patient population.
PURPOSE: The purpose of this study was to study the use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography (F-18 FDG PET) for monitoring therapeutic response by rhabdomyosarcoma (RMSA) in children. PATIENTS AND METHODS: A retrospective case study was performed by searching a computer database for the patients with RMSA in whom F-18 FDG PET studies were performed pre- and posttreatment. The data of the PET studies from these patients were analyzed in conjunction with clinical treatment and other imaging studies to determine whether interval changes of F-18 FDG uptake by the RMSA reflect response of RMSA to treatment. RESULTS: Four patients with RMSA who received both pretreatment and posttreatment F-18 FDG PET studies were identified from the database and included in this study. A dramatic decrease of F-18 FDG uptake by the tumor was evident in the patients who had a favorable response to the therapy and prolonged remission of the disease. In contrast, persistent abnormal FDG uptake in one patient was associated with early relapse of the RMSA. CONCLUSIONS:F-18 FDG PET may be useful for monitoring therapeutic response by RMSA in children, which needs to be verified with a prospective study in a larger patient population.
Authors: Anuradha Soundararajan; Jinu Abraham; Laura D Nelon; Suresh I Prajapati; Lee Ann Zarzabal; Joel E Michalek; Stanton F McHardy; Douglas S Hawkins; Suman Malempati; Charles Keller Journal: Pediatr Blood Cancer Date: 2012-01-11 Impact factor: 3.167
Authors: A Yuriko Minn; Elizabeth R Lyden; James R Anderson; Lynn Million; Carola A Arndt; Kenneth Brown; Douglas S Hawkins; Sarah S Donaldson Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Nicole J M Freling; Johannes H M Merks; Peerooz Saeed; Alfons J M Balm; Johannes Bras; Bradley R Pieters; Judit A Adam; Rick R van Rijn Journal: Pediatr Radiol Date: 2010-08-20
Authors: A C M van de Luijtgaarden; J W J de Rooy; L F de Geus-Oei; W T A van der Graaf; W J G Oyen Journal: Cancer Imaging Date: 2008-10-04 Impact factor: 3.909
Authors: Rick R Van Rijn; Jim C H Wilde; Johannes Bras; Foppe Oldenburger; Kieran M C McHugh; Johannes H M Merks Journal: Pediatr Radiol Date: 2008-03-07